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Several causes of eosinophilic pleural eﬀusions have been described with malignancy being the commonest cause. Hypere-
osinophilic syndrome (HES) is a rare disease and very few cases have been reported of HES presenting as eosinophilic pleural
eﬀusion (EPE). We report a case of a 26-year-old male who presented with shortness of breath. He had bilateral pleural eﬀusions,
generalized lymphadenopathy, splenomegaly, and leukocytosis with marked peripheral blood eosinophilia. The pleural ﬂuid was
exudative, with 25%–30% eosinophilis, and absence of neoplastic cells. Hypereosinophilic syndrome was diagnosed after other
causes of eosinophilia were excluded. He continued to be dyspneic with persistent accumulation of eosinophilic pleural ﬂuid, even
after his peripheral eosinophil count had normalized in response to treatment. This patient represents a very unusual presentation
of HES with dyspnea and pleural eﬀusions and demonstrates that treatment based on response of peripheral eosinophil counts, as
is currently recommended, may not always be clinically adequate.
Copyright © 2009 Ndubuisi C. Okafor et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Eosinophilic pleural eﬀusion (EPE) is deﬁned as pleural
ﬂuid with 10% or more eosinophils [1]. Eosinophilic pleural
eﬀusions are uncommon with an incidence of 7.2% of all
pleural eﬀusions [1]. The pathogenesis of EPE involves
increased production of eosinophils in the bone marrow,
migration to the lungs, and extended survival of the
eosinophils due to impaired apoptosis by IL-5, IL-3, and
GM-CSF[2].ThecausesofEPEinorderoffrequencyinclude
malignancy (34.8%), infections (19.2%), unknown (14.1%),
posttraumatic (8.9%), and miscellaneous (23%) [1].
Hypereosinophilic syndrome (HES) is deﬁned as periph-
eral eosinophilia of 1.5 × 109 /L, evidence of end-organ
involvement, and lack of evidence for other causes of
eosinophilia [3]. Hypereosinophilic syndrome can be clas-
siﬁed as Myeloproliferative HES, Lymphocytic HES, Unde-
ﬁned HES, Familial HES, Associated HES, and Overlap
HES [3]. Treatment of EPE is based on control of the
underlying disease [1] and treatment of HES is based on
control of the peripheral eosinophilia [4], which did not
appear appropriate for our patient.
2. Case Presentation
26-year-old African American male presented with shortness
of breath of over two months. He was previously healthy and
had a normal CBC and diﬀerential eighteen months prior
to admission. CT scan showed bilateral pleural eﬀusions,
generalized lymphadenopathy, ascites, and splenomegaly
(Figure 1). Pleural ﬂuid analysis and cytology showed an
inﬂammatory inﬁltrate, reactive mesothelial cells, and 25%–
30% eosinophils. No neoplastic cells were identiﬁed. Glu-
cose, LDH, lipase, and amylase were normal. The pH
was alkaline (7.53) and protein was consistent with an
exudative eﬀusion. CBC revealed a leukocytosis of 44.6 ×
109/L; absolute eosinophil count (AEC) was 35.6 × 109/L.
Peripheral blood smear, lymph node biopsy, and bone
marrow aspiration showed eosinophilia with normal mor-
phology, lymphoid hyperplasia, and hypercellular marrow
with eosinophilia, respectively.
Other studies for parasitic infection, HIV, and TB were
negative. Bone marrow ﬂow cytometry showed polytypic
B cells. FISH analysis and PCR assay for FIP1L1-PDGFRA
fusion transcript did not detect an abnormality. A trans-
thoracic echocardiography showed left ventricular ejection2 Case Reports in Medicine
Table 1: Pleural ﬂuid (PF) analysis at monthly intervals. This shows that the eosinophilia in pleural ﬂuid persisted for months despite
therapy.
PF analysis 1 PF analysis 2 PF analysis 3
(Day 3) (Day 30) (Day 64)
pH 7.53 — —
Lipase U/L — <10 10
LDH U/L 94 79 458
Protein g/dL 4.88 4.61 <1.0
Glucose mg/dL 96 — 37
Amylase U/L <10 — <10
Nucleated cell count 1530 580 1300
Red blood cells 450 625 12640
Neutrophils 21 26 76
Mononuclear 54 41 17
Mesothelial 25 33 7
Abnormal cells 0 0 0
Culture Negative Negative Staph. aureus
Cytology 25%–30% eosinophils 25% eosinophils Primarily eosinophils
No neoplastic cells No neoplastic cells No neoplastic cells
LDH: Lactate dehydrogenase.
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Figure 1: Chest radiography and CT scan of the chest showing
bilateral pleural eﬀusions.
fraction55%–60%withnodiastolicdysfunction.Adiagnosis
of hypereosinophilic syndrome was made by exclusion. As
initial treatment of hydroxycarbamide provided no clinical
beneﬁt or reduction in the eosinophilia, prednisone was
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Figure 2: The eﬀect of treatment on the absolute eosinophil
count (AEC) in peripheral blood. Eosinophilia normalizes with
hydroxycarbamide plus prednisone. Total pleural ﬂuid removed
each week was unaltered by treatment adequate to normalize
peripheral eosinophil counts.
added with prompt reduction of the eosinophilia. A trial
of imatinib was given despite negative FIP1L1-PDGFRA
without beneﬁt. He had recurrent pleural eﬀusions requiring
repeated thoracentesis which continued to demonstrate
persistent elevated eosinophil counts (Table 1). A permanent
catheter was placed in the right pleural space and accessed
for thoracentesis of about two liters every three to ﬁveCase Reports in Medicine 3
days along with repeated large volume paracentesis for
persistent ascites. Figure 2 shows that despite normalization
of the patient’s peripheral eosinophilia, his pleural eﬀusions
remained refractory to therapy. Four months after his initial
presentation, he developed bilateral empyemas with methi-
cillin resistant staphyloccus aureus as a complication of mul-
tiple thoracentesis, rapidly deteriorated in spite of aggressive
management and died from multiple organ dysfunction.
3. Discussion
Hypereosinophilic syndrome rarely presents with eosino-
philic pleural eﬀusion. If pleural eﬀusions are present in
HES, they typically result from heart failure due to cardiac
eosinophilic disease [3]. However, our patient had a normal
trans-thoracic echocardiography and beta natriuretic pep-
tide. In addition, the pleural eﬀusion of the three previously
reportedpatientsresolvedrapidlywithclinicalimprovement,
using treatment recommendations for HES of normalizing
the peripheral eosinophilia [5–7]. Despite rapid reduction of
the peripheral eosinophilia in our patient, the eosinophilic
pleural eﬀusion continued to accumulate for months ques-
tioning this therapeutic recommendation. A recent review
of patients with EPE reported 2 out of 135 patients with
percentage of eosinophils in peripheral blood higher than in
pleural ﬂuid. Those two patients had hematological malig-
nancies [1]. Our patient had features of both the myelopro-
liferative and the lymphocytic variants of HES. He likely had
Unclassiﬁed Complex HES. There are several chemotherapy
choices depending on the variant of HES and new drugs are
in clinical trials [3]. Our patient expired prior to receiving
alternate treatment; however, it should be noted that the
recommendation of titrating these therapies as well is nor-
malization of the peripheral eosinophilia which had already
been obtained in our patient but without clinical beneﬁt.
4. Conclusion
Treatmentofeosinophilicpleuraleﬀusionsisdirectedtoward
the underlying cause, in this case hypereosinophilic syn-
drome. Disease remission cannot be determined by resolu-
tion of peripheral eosinophilia alone but also by the absence
of recurrence or progression of end-organ damage [8].
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